Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics Gets NYSE Amex Extension for Stock Listing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Interleukin Genetics today said that the corporate compliance staff of the New York Stock Exchange Amex has granted the firm an extension to meet the exchange's continued listing standards.

The Waltham, Mass.-based genetic test maker will remain listed on the NYSE Amex up to June 23, subject to periodic review by the exchange staff of the firm's progress toward regaining compliance.

Interleukin had received a letter of non-compliance from the New York Stock Exchange Alternext, which now includes listings on Amex following the NYSE's acquisition, in December 2008 saying that the firm was not in compliance with the exchange's regulations. Its stockholders' equity was less than $6 million and it had reported losses from continuing operations and net losses in its five most recent fiscal years leading up to the letter.

Two months ago, Interleukin filed a shelf registration with the US Securities and Exchange Commission seeking to sell up to $75 million worth of stock or debt instruments.

The firm is scheduled to release its fourth-quarter and fiscal-year 2009 results later this week.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.